Adderall's U.S. Market: ADHD, Shortages, and Counterfeiting
This paper analyzes the presence of Adderall in the U.S. pharmaceutical market since its 1996 introduction, tracing its rapid growth alongside rising ADHD diagnoses. It examines Shire Pharmaceuticals' commercial dominance, the role of the DEA in restricting supply, and the paradox of shortages that nonetheless boosted branded sales. The paper also addresses the dangers posed by counterfeit Adderall circulating through informal and online channels, arguing that vulnerable patients — unable to function without the drug — are exploited by pharmaceutical companies, regulators, and counterfeiters alike. The analysis draws on consumer behavior literature and health industry reporting to situate Adderall within broader debates about drug access and patient welfare.
- Introduction: Adderall and the ADHD Market: ADHD prevalence drives demand for Adderall
- Origins and Rapid Growth of Adderall: Shire creates Adderall; millions of prescriptions written
- DEA Restrictions and the Paradox of Shortages: DEA limits supply; Shire profits despite shortages
- Counterfeiting and Supply Chain Risks: Fake Adderall proliferates online, endangering patients
- Patient Vulnerability and Market Exploitation: Dependent patients exploited by multiple market actors
- Conclusion: Growing ADHD diagnoses worsen critical market conditions
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Integrates direct quotations from academic and journalistic sources to substantiate market claims without over-relying on opinion.
- Moves logically from historical context to regulatory conflict to patient harm, building a coherent argument about systemic exploitation.
- Grounds abstract market analysis in concrete human consequences, making the argument accessible and persuasive.
Key academic technique demonstrated
The paper demonstrates effective use of source synthesis: rather than treating each citation in isolation, the author weaves together pharmaceutical history, DEA policy, consumer behavior research, and industry reporting to construct a unified argument about how multiple actors — Shire, regulators, and counterfeiters — simultaneously profit from or contribute to patient vulnerability. This layered synthesis is a hallmark of undergraduate analytical writing.
Structure breakdown
The paper opens with epidemiological context to establish market demand, then narrates Adderall's corporate origins. It pivots to DEA restrictions and the counterintuitive effect on branded sales, before examining counterfeit risks supported by consumer behavior literature. The paper closes by zooming out to a broader critique of exploitation. Each section builds on the previous, maintaining a clear argumentative thread throughout.
Introduction: Adderall and the ADHD Market
With between 3% and 5% of individuals in the U.S. having been diagnosed with ADHD, there is high demand for drugs that enable these individuals to cope with their condition. While there is much controversy surrounding such drugs, some are considered especially effective and maintain a strong consumer base. During the last two decades, Adderall experienced significant growth in the healthcare industry as people acknowledged the benefits the drug offered ADHD patients.
During the late 1990s and early 2000s, the public began to express greater support for stimulant-based treatments, with individuals from a wide range of backgrounds improving their lives as a result of using them. To a certain degree, the rising prominence of ADHD as a recognized diagnosis played an important role in helping a number of pharmaceutical companies achieve substantial growth.
Origins and Rapid Growth of Adderall
Adderall was created in 1996 as a consequence of Shire acquiring Rexar Pharmaceuticals and rebranding one of its diet drugs, Obetrol. The company immediately brought the product to market after receiving FDA approval. "Overnight, Adderall catapulted Shire from a small-time drug company into a major pharmaceutical giant" (Mayes, Bagwell, & Erkulwater 154). Adderall is currently one of the most popular drugs prescribed for individuals with ADHD and a range of related disorders. From its introduction in 1996 through 2006, doctors wrote approximately 50 million prescriptions for children and adults (Mayes, Bagwell, & Erkulwater 154).
DEA Restrictions and the Paradox of Shortages
In order to develop a fuller understanding of Adderall, Shire, and the company's relationship with the market, one must consider recent shortages of the drug. Shire has claimed that the Drug Enforcement Administration (DEA) implemented strategies designed to limit the drug's production. As a consequence, individuals who depend on it in order to live relatively normal lives have been forced into scavenger hunts in an attempt to obtain it. Many visit numerous pharmacies only to find that the drug is either unavailable or sold out as soon as it arrives. Because Adderall is a controlled substance, the DEA has expressed concern that it could become too widely available. The agency has accordingly introduced tougher regulations to limit its presence in pharmacies and to discourage use among individuals who do not medically require it (Edwards).
While ADHD sufferers face significant difficulties obtaining Adderall, Shire profits considerably from the situation. This is particularly surprising given that several generic drugs use the same formulation as Adderall. "Usually, branded sales collapse almost immediately as insurers and pharmacists switch all their patients to the cheap, identical version of the drug" (Edwards). In Adderall's case, however, branded sales remained strong even amid reported shortages — a paradox that underscores the unusual market dynamics surrounding this medication.
Conclusion
Adderall has become one of the most sought-after medicines in the United States, with ADHD patients requiring it on a daily basis in order to function properly. The apparent increase in the prevalence of the disorder in recent years only worsens these conditions, making the market increasingly critical. With patients in a vulnerable position, companies such as Shire, along with a range of other actors, continue to interfere and profit from their difficulties.
Works Cited
Edwards, J. "How a 'Shortage' of Adderall Actually Increased Sales of the ADHD Drug." CBS News, 17 Aug. 2015.
Kardes, Frank R., Maria L. Cronley, and Thomas W. Cline. Consumer Behavior. South-Western Cengage Learning, 2011.
Mayes, Rick, Catherine Bagwell, and Jennifer L. Erkulwater. Medicating Children: ADHD and Pediatric Mental Health. Harvard University Press, 2009.
Always verify citation format against your institution’s current style guide requirements.